查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1411530

CAR T 細胞治療市場：依適應症、最終用途分類 - 2024-2030 年全球預測

CAR T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumors), End-Use (Cancer Treatment Centers, Hospitals) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年CAR-T細胞治療市場規模為50.8億美元，預計2024年將達53.5億美元，2030年將達到71.5億美元，複合年成長率為5.00%。

CAR T細胞療法的全球市場

主要市場統計
基準年[2023] 50.8億美元
預測年份 [2024] 53.5億美元
預測年份 [2030] 71.5億美元
複合年成長率（%） 五％
CAR T細胞治療市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估CAR T細胞治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對 CAR T 細胞治療市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-CAR T細胞治療市場的市場規模與預測是多少？

2-CAR T 細胞治療市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3-CAR T細胞治療市場的技術趨勢和法律規範是什麼？

4-CAR T細胞治療市場主要廠商的市場佔有率是多少？

進入5-CAR T細胞治療市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 多發性骨髓瘤、淋巴瘤和白血病的發生率上升
      • 根據政府認可，可以適當報銷 CAR T 細胞治療
      • 基因和細胞療法的採用增加
    • 抑制因素
      • CAR T 細胞免疫療法有效性的限制
    • 機會
      • 本土 CAR-T 療法的突破性研發資金和合作夥伴關係
      • 政府對引進CAR T細胞免疫療法的支持與承諾
    • 任務
      • 對安全性和可能的​​副作用的擔憂
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章 CAR T 細胞治療市場（依適應症）

  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 骨髓瘤
  • 固態腫瘤
    • 大腦和中樞神經系統
    • 肝癌
    • 黑色素瘤

第7章 CAR T 細胞治療市場：依最終用途

  • 癌症治療中心
  • 醫院

第8章美洲CAR T細胞治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區CAR T細胞治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲CAR T細胞治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第12章競爭產品組合

  • 主要公司簡介
    • AbClon Inc.
    • Abintus Bio, Inc.
    • AffyImmune Therapeutics Inc.
    • Aleta Biotherapeutics
    • Amgen Inc.
    • Anixa Biosciences, Inc.
    • Aurora BioPharma, Inc.
    • Autolus Therapeutics PLC
    • Bellicum Pharmaceuticals, Inc.
    • BioNTech SE
    • Bristol-Myers Squibb Company
    • CARsgen Therapeutics Holdings Limited by Huadong Medicine Co., Ltd.
    • Cellectis SA
    • Celyad Oncology SA
    • Fate Therapeutics, Inc.
    • Gilead Sciences, Inc.
    • Intellia Therapeutics, Inc.
    • Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
    • Legend Biotech Corporation by Genscript Biotech Corporation
    • Les Laboratories Servier
    • Mustang Bio by Fortress Biotech, Inc.
    • Noile-immune Biotech, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sorrento Therapeutics, Inc.
  • 主要產品系列

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-1E2F1ED7E6BC

[195 Pages Report] The CAR T-cell Therapy Market size was estimated at USD 5.08 billion in 2023 and expected to reach USD 5.35 billion in 2024, at a CAGR 5.00% to reach USD 7.15 billion by 2030.

Global CAR T-cell Therapy Market

KEY MARKET STATISTICS
Base Year [2023] USD 5.08 billion
Estimated Year [2024] USD 5.35 billion
Forecast Year [2030] USD 7.15 billion
CAGR (%) 5%
CAR T-cell Therapy Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the CAR T-cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the CAR T-cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the CAR T-cell Therapy Market, highlighting leading vendors and their innovative profiles. These include AbClon Inc., Abintus Bio, Inc., AffyImmune Therapeutics Inc., Aleta Biotherapeutics, Amgen Inc., Anixa Biosciences, Inc., Aurora BioPharma, Inc., Autolus Therapeutics PLC, Bellicum Pharmaceuticals, Inc., BioNTech SE, Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited by Huadong Medicine Co., Ltd., Cellectis SA, Celyad Oncology SA, Fate Therapeutics, Inc., Gilead Sciences, Inc., Intellia Therapeutics, Inc., Janssen Global Services, LLC by Johnson & Johnson Services, Inc., Legend Biotech Corporation by Genscript Biotech Corporation, Les Laboratories Servier, Mustang Bio by Fortress Biotech, Inc., Noile-immune Biotech, Inc., Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the CAR T-cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Hematologic Malignancies
      • Leukemia
      • Lymphoma
      • Myeloma
    • Solid Tumors
      • Brain & Central Nervous System
      • Liver Cancer
      • Melanoma
  • End-Use
    • Cancer Treatment Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the CAR T-cell Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the CAR T-cell Therapy Market?

3. What are the technology trends and regulatory frameworks in the CAR T-cell Therapy Market?

4. What is the market share of the leading vendors in the CAR T-cell Therapy Market?

5. Which modes and strategic moves are suitable for entering the CAR T-cell Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. CAR T-cell Therapy Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence of multiple myeloma cancer, lymphoma and leukemia
      • 5.1.1.2. Availability of adequate reimbursements for CAR T-cell therapy with government awareness
      • 5.1.1.3. Increasing adoption of gene and cell therapy
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations of the efficacy of CAR T-cell immunotherapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Exponential R&D funding and partnership for indigenous CAR-T therapy
      • 5.1.3.2. Government support and initiative for the adoption of CAR T-cell immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with safety and possible side effects
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. CAR T-cell Therapy Market, by Indication

  • 6.1. Introduction
  • 6.2. Hematologic Malignancies
    • 6.3.1. Leukemia
    • 6.3.2. Lymphoma
    • 6.3.3. Myeloma
  • 6.3. Solid Tumors
    • 6.4.1. Brain & Central Nervous System
    • 6.4.2. Liver Cancer
    • 6.4.3. Melanoma

7. CAR T-cell Therapy Market, by End-Use

  • 7.1. Introduction
  • 7.2. Cancer Treatment Centers
  • 7.3. Hospitals

8. Americas CAR T-cell Therapy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific CAR T-cell Therapy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa CAR T-cell Therapy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. AbClon Inc.
    • 12.1.2. Abintus Bio, Inc.
    • 12.1.3. AffyImmune Therapeutics Inc.
    • 12.1.4. Aleta Biotherapeutics
    • 12.1.5. Amgen Inc.
    • 12.1.6. Anixa Biosciences, Inc.
    • 12.1.7. Aurora BioPharma, Inc.
    • 12.1.8. Autolus Therapeutics PLC
    • 12.1.9. Bellicum Pharmaceuticals, Inc.
    • 12.1.10. BioNTech SE
    • 12.1.11. Bristol-Myers Squibb Company
    • 12.1.12. CARsgen Therapeutics Holdings Limited by Huadong Medicine Co., Ltd.
    • 12.1.13. Cellectis SA
    • 12.1.14. Celyad Oncology SA
    • 12.1.15. Fate Therapeutics, Inc.
    • 12.1.16. Gilead Sciences, Inc.
    • 12.1.17. Intellia Therapeutics, Inc.
    • 12.1.18. Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
    • 12.1.19. Legend Biotech Corporation by Genscript Biotech Corporation
    • 12.1.20. Les Laboratories Servier
    • 12.1.21. Mustang Bio by Fortress Biotech, Inc.
    • 12.1.22. Noile-immune Biotech, Inc.
    • 12.1.23. Novartis AG
    • 12.1.24. Pfizer Inc.
    • 12.1.25. Sorrento Therapeutics, Inc.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. CAR T-CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CAR T-CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. CAR T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CAR T-CELL THERAPY MARKET DYNAMICS
  • FIGURE 7. CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 10. CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. CAR T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. CAR T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. CAR T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. CAR T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 6. CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 8. CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CAR T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. CAR T-CELL THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 13. CAR T-CELL THERAPY MARKET SIZE, BY BRAIN & CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CAR T-CELL THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CAR T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 17. CAR T-CELL THERAPY MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. CAR T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 188. CAR T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. CAR T-CELL THERAPY MARKET LICENSE & PRICING